References
[1] Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents.2020; 55(5):105955.
[2] Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. A pathological report of three COVID-19 cases by minimal invasive autopsies. Zhonghua Bing Li Xue Za Zhi. 2020; 49(5):411-417.
[3] Li JW, Han TW, Woodward M, Anderson CS, Zhou H, Chen YD, et al. The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis [published online ahead of print, 2020 April 16]. Prog Cardiovasc Dis. 2020; S0033-0620(20):30080-3.
[4] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 February 7]. JAMA. 2020; 323(11):1061-1069.
[5] Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41(2):139-144.
[6] Wang D, Li S, Jiang J, Yan J, Zhao C, Wang Y, et al. Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci. 2019; 62(2):187-202.
[7] Silva E, Montenegro JS, Estupiñán MC, Arias G, Osorio JP, Poveda CM, et al. Fulminant myocarditis due to the influenza B virus in adults: Report of two cases and literature review. Miocarditis fulminant eenadultosporel virus de la influenza B: reporte de dos casos y revisión de la literatura. Biomedica. 2019; 39(Supl. 2):11-19.
[8] Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options [published online ahead of print, 2020 April 30]. Cardiovasc Res. 2020; cvaa106.
[9] Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin [pub-lished online ahead of print, 2020 March 16]. Eur Heart J. 2020; ehaa190.
[10] Kow CS, Hasan SS. Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis [published online ahead of print, 2020 May 10]. Infection. 2020;1-2. https://doi.org/10.1007/s15010-020-01441-4.
[11] Lv J, Han B, Wang C, Wang J, Jiang D, Zhao L, et al. The Clinical Features of Children With Acute Fulminant Myocarditis and the Diagnostic and Follow-Up Value of Cardiovascular Magnetic Resonance. Front Pediatr. 2019; 7:388. Published 2019 October 1.
[12] Wei X, Fang Y, Hu H. Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis. Eur Heart J. 2020; 41(22):2122.
[13] Leurent G, Langella B, Fougerou C, Lentz PA, Larralde A, Bedossa M, et al. Diagnostic contributions of cardiac magnetic resonance imaging in patients presenting with elevated troponin, acute chest pain syndrome and unobstructed coronary arteries. Arch Cardiovasc Dis. 2011; 104(3):161-170.
[14] Mosebach CM, Tandon V, Kumar M. Acute Myocarditis Presenting as Acute Coronary Syndrome. Cureus. 2019; 11(7):e5212. Published 2019 July 23.
[15] Punja M, Mark DG, McCoy JV, Javan R, Pines JM, Brady W. Electrocardiographic manifestations of cardiac infec-tious-inflammatory disorders. Am J Emerg Med. 2010; 28(3):364-377.
[16] Kang TD, Ren YL, Zhao H, Ning SQ and Liu WX. Risk factors for adverse cardiac events in adults with fulminant myocarditis during hospitalization. World J Clin Cases. 2020; 8(2):255-263.
[17] Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and Cardiovascular Disease. Circula-tion.2020; 141(20):1648-1655.
[18] Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A.Myocardial injury and COVID-19: Possible mechanisms. Life Sci. 2020; 253:117723.
[19] Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020; 55(6):105982.
[20] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 January 30]. Lancet. 2020; 395(10223):497-506.
[21] Mahmud E, Dauerman HL, Welt FGP, Messenger JC, Rao SV, Grines C, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic [published online ahead of print, 2020 April 21]. J Am Coll Cardiol. 2020; S0735-1097(20)35026-9.
[22] Bassetti M, Giacobbe DR, Aliberti S, Barisione E, Centanni S, De Rosa FG, et al. Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect. 2020; 26(7):880-894.
[23] ŞŞentürk M, El Tahan MR, Szegedi LL, Marczin N, Karzai W, Shelley B, et al. Thoracic Anesthesia of Patients With Suspected or Confirmed 2019 Novel Coronavirus Infection: Preliminary Recommendations for Airway Management by the European Association of Cardiothoracic Anaesthesiology Thoracic Subspecialty Committee [published online ahead of print, 2020 April 11]. J CardiothoracVascAnesth. 2020; S1053-0770(20)30309-8.
[24] Rewa OG, Villeneuve PM, Lachance P, Eurich DT, Stelfox HT, Gibney RTN, et al. Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review. Intensive Care Med. 2017; 43(6):750-763.
[25] Chou HW, Wang CH, Lin LY, Chi NH, Chou NK, Yu HY, et al. Prognostic factors for heart recovery in adult patients with acute fulminant myocarditis and cardiogenic shock supported with extracorporeal membrane oxygenation. J Crit Care. 2020; 57:214-219.